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Abstract
Background: It has been postulated that atypical and melancholic depression subtypes exist in depressed 
fibromyalgia (FM) patients, yet no study has empirically tested this hypothesis. The purpose of this study is to 
determine whether major depressive disorder (MDD) with atypical features and MDD with melancholic features occurs 
in a FM sample and to describe their demographic, clinical and diagnostic characteristics.
Methods: An observational cohort study using a descriptive cross-sectional design recruited a convenience sample of 
76 outpatients with FM from an academic Rheumatology clinic and a community mental health practice. Diagnoses of 
FM were confirmed using the 1990 ACR classification guidelines. Diagnoses of MDD and diagnostic subtypes were 
determined using the DSM-IV-TR criteria. Clinical characteristics were measured using the Fibromyalgia Impact 
Questionnaire, Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression 
Supplement and other standardized instruments. Odds ratios were computed on subtype-specific diagnostic criteria. 
Correlations assessed associations between subtype diagnoses and diagnostic criteria.
Results: Of the 76 subjects with FM, 11.8% (n = 9) were euthymic, 52.6% (n = 40) met diagnostic criteria for MDD with 
atypical features and 35.6% (n = 27) for MDD with melancholic features. Groups did not differ on demographic 
characteristics except for gender (p = 0.01). The non-depressed and atypical groups trended toward having a longer 
duration of FM symptoms (18.05 yrs. ± 12.83; 20.36 yrs. ± 15.07) compared to the melancholic group (14.11 yrs. ± 8.82; p 
= 0.09). The two depressed groups experienced greater severity on all clinical features compared to the non-depressed 
group. The atypical group did not differ clinically from the melancholic group except the latter experienced greater 
depression severity (p = 0.001). The atypical group demonstrated the highest prevalence and correlations with 
atypical-specific diagnostic criteria: (e.g., weight gain/ increased appetite: OR = 3.5, p = 0.02), as did the melancholic 
group for melancholic-specific criteria: (e.g., anhedonia: OR = 20, p < 0.001).
Conclusion: Depressed fibromyalgia patients commonly experience both atypical and melancholic depressive 
features; however, in this study, atypical depression was 1.5 times more common than melancholic depression. This 
finding may have significant research and clinical implications.
Background
Fibromyalgia (FM) is a common, chronic and often debil-
itating rheumatologic disorder which presents in 7% of all
primary care visits [1]. FM is characterized by widespread
musculoskeletal pain (100%), specified tender points
(100%), fatigue (96-100%), sleep disturbances (86%-98%),
and co-morbid mood disorders (29%) [2]. While the life-
time prevalence rate of major depressive disorders in the
general population is 10% to 25% for women and from 5%
to 12% for men [3], 74% of FM patients report at least one
major depressive disorder (MDD) episode in their life-
time [4]. Depression is known to worsen FM symptom
severity including pain, functional impairment, sleep
quality and quality of life [5-7]. Of grave concern is sui-
cide is the leading cause of premature mortality in those
with FM. People with FM have been reported to have a
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nine-fold increased risk of death from suicide during
depressive episodes [8]. It is important to further eluci-
date the biological and psychological underpinnings of
depression in FM, as the successful treatment of depres-
sion has been shown to significantly improve FM symp-
tomatology [9].
While several subtypes of MDD have been discussed in
the literature, only three have specific diagnostic criteria
defined in the Diagnostic and Statistical Manual, 4 th edi-
tion, Text Revised (DSM-IV-TR) [10]: MDD with psy-
chotic features, MDD with atypical features and MDD
with melancholic features. Full diagnostic criteria can be
viewed in an additional file (#1).Combined, the atypical
and melancholic subtypes represent approximately 60%
of all MDD cases [11] and have been postulated to repre-
sent the two main subtypes of depression in FM [12], thus
are the focus of this study.
Major depressive disorder, with atypical and melan-
cholic features, has been methodically investigated in
depressed populations: yet there is still some debate as to
the validity of the subtype-specific criteria, especially for
atypical depression [13]. While several researchers have
critiqued the current DSM-IV-TR criteria, as yet a viable
alternative has not been agreed upon [14]. Therefore, for
the purpose of this study, the current prevailing criteria
as per the DSM-IV-TR were used. Gold and Chrousos
[15] postulated that atypical depression would be more
prevalent in FM patients compared to melancholic
depression due to the shared biological underpinnings of
atypical depression and FM. Specifically, there is a blunt-
ing of hypothalamic-pituitary-adrenal (HPA) axis func-
tioning as evidenced by low to normal levels of plasma
cortisol following dexamethasone suppression testing.
This blunting is secondary to glucocorticoid receptor
desensitization as a result of chronic over secretion of
cortisol. However, there are no studies to date that have
evaluated Gold and Chrousos' assertions. Thus the first
aim of this study was to test the hypotheses that atypical
depressive episodes (ADE) and melancholic depressive
episodes (MDE) occur in FM patients with ADE being the
predominant subgroup. A secondary aim was to describe
the demographic and clinical characteristics and diagnos-
tic features of depression subgroups in people with FM to
determine if they exhibited the same symptom clusters as
those in depressed, non-FM samples.
Methods
Sample and data collection
Subjects were recruited from an academic medical center
in the Pacific Northwest and a local community mental
health clinic. A multi-step recruitment protocol was used
to invite subjects to enter the study [16]. Males and
females 18 years old or older who were diagnosed with
FM as per the 1990 American College of Rheumatology
criteria [17] for ≥ 2 years were eligible to participate in the
study. Subjects also needed to speak and read English at a
6 th grade level. Exclusion criteria, designed to decrease
risk to subjects and potential confounding variables,
excluded subjects who were acutely ill, pregnant, cur-
rently lactating or planning to conceive within 90 days.
Additional exclusion criteria included a Beck Depression
Inventory score greater than 31 (extreme depression), any
medical disorder that altered the HPA axis, suicidal ide-
ation, abnormal thyroid stimulating hormone levels (less
than 0.28 uIU/ml or greater than 5.00 uIU/ml), weight
change greater than 15 pounds during the prior three
months and subjects who did not meet diagnostic criteria
for one of the three FM groups, i.e.: non-ADE or non-
MDE (n = 1). Subjects on medications that could poten-
tially alter the HPA axis were also excluded (e.g.: predni-
sone, opioids, corticosteroids, carbamazepine, etc.).
Those on anti-depressants were not excluded, as research
has shown the presence or absence of antidepressants
while depressed, type of antidepressant or number of
antidepressant trials previously used did not affect HPA
axis perturbations or cortisol levels (unless depression
symptoms had resolved) following the combined dexam-
ethasone suppression/ corticotrophin-releasing hor-
mone (DEX/CRH) test [18]. Thus depressed subject's
plasma cortisol levels, which are associated with subtype-
specific symptom expression, would still be expected to
reflect MDD subtype variations. Approval of the protocol
was obtained from the university's Investigational Review
Board. Data was collected from 01/07/2006 to 10/18/
2006.
Protocol
The first visit was held at the University's School of Nurs-
ing in a town hall meeting format. All subjects gave writ-
ten informed consent after an explanation of the study's
purpose and procedures was given. Screening informa-
tion for depression, demographic data, current medica-
tions and medical history were obtained and inclusion/
exclusion criteria were assessed. In an attempt to
decrease the possibility of estrogen fluctuations affecting
symptom presentation, (e.g., fatigue, amotivation, hyper-
phagia and hypersomnia), menstruating females who
continued to meet criteria were encouraged to schedule
and attend the second visit during their next luteal phase
(14 days after the first day of their last menstrual cycle),
when estrogen levels would theoretically be at their high-
est. Menstrual phase was determined from subjective
reports of the number of days from the first day of the last
menstrual period. All other subjects were scheduled
within 30 days of their first assessment.
At visit 2, subjects completed self-report instruments
plus interviewer-administered evaluations. To decrease
inter-rater reliability issues, the principal investigator (PI)Ross et al. BMC Musculoskeletal Disorders 2010, 11:120
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completed all physical examinations and interviewer-
administered questionnaires for all subjects. The follow-
ing instruments, chosen specifically for their psychomet-
ric properties and appropriateness for use in an FM
population, were used to assess depression severity, sub-
type-specific diagnostic criteria, overall FM symptom
severity, pain severity, functional impairment, quality of
life and sleep quality.
Primary measures
The 2003 version of the Structured Interview Guide for
the Hamilton Depression Rating Scale with Atypical
Depression Supplement (SIGH-ADS) was used to assess
overall depression severity and severity of subtype-spe-
cific diagnostic features. This interviewer-administered
questionnaire is based on the 21-item Hamilton Depres-
sion Rating Scale (HAM-D) plus includes an 8-item
addendum to assess atypical depressive episode (ADE)
features [19]: social withdrawal, increased appetite,
increased eating, weight gain, carbohydrate craving or
eating, hypersomnia, fatigability and pattern of depres-
sion symptoms being worse in the afternoon. It also
includes two un-scored questions regarding difficulty
awakening and temperature discomfort that are indica-
tive of ADE. The HAM-D also includes seven items that
assess features of melancholic depressive episode (MDE)
features as per the DSM-IV-TR [10]: loss of appetite,
weight loss, terminal insomnia, guilt, agitation, psycho-
motor retardation and pattern of depression symptoms
being worse in the morning. Scores range from 0 to 88
with lower scores reflective of lower depression severity.
Reliability for scale items of the SIGH-ADS as measured
by Cronbach's alpha was established to be 0.87 in this
sample.
T o  i n s u r e  i n s t r u m e n t a l  v a l i d i t y  o f  t h e  S I G H - A D S ,  a
patient self report version was used to verify the inter-
viewer-obtained responses. The Structured Interview
Guide for the Hamilton Depression Rating Scale, Seasonal
Affective Disorder- Self Report Version (SIGH-SAD-
SR)[20] includes the same questions as the SIGH-ADS
and has the same scoring matrix. After the SIGH-ADS
was administered, the self-report questionnaire was
reviewed by the PI. If responses differed by two or more
points on any question, the PI clarified the question with
the subject and rescored it accordingly. Reliability for
scale items of the SIGH-SAD-SR as measured by Cron-
bach's alpha was established to be 0.78 in this sample.
The DSM-IV-TR diagnostic criteria for MDD with
atypical features and MDD with melancholic features [10]
were used to diagnose depressive subtypes. Based on
these criteria, subjects were divided into three groups: A.
non-depressed FM patients, B. FM patients with a cur-
rent ADE and C. FM patients with a current MDE. As
only one depressed FM subject did not meet diagnostic
criteria for either ADE or MDE (non-ADE/non-MDE, n =
1), this data could not be used for group comparisons,
thus was excluded from all statistical analyses.
The Fibromyalgia Impact Questionnaire(FIQ) was used
to measure clinical features of FM, including pain sever-
ity, functional impairment, fatigue and depression. The
FIQ was developed to measure the components of health
s t a t u s  b e l i e v e d  t o  b e  m o s t  a f f e c t e d  b y  F M  s y m p t o m
severity, impact on functionality and response to treat-
ment and outcomes in interventional studies [21]. Total
FIQ scores range from 0 to 100, with higher values indi-
cating a more negative impact of FM. The test-retest reli-
ability has been documented to range from 0.56 on the
pain score to 0.95 for physical function [22]. Internal con-
sistency as measured by Cronbach's alpha has been estab-
lished to range from 0.72 to 0.93 in seven translated
versions of the FIQ. Reliability for scale items of the FIQ
as measured by Cronbach's alpha was established to be
0.85 in this sample.
Three instruments were used to measure pain dimen-
sions: the FIQ visual analogue scale (VAS) for pain, the
number of tender points and the cumulative myalgic score
(CMS). The 100-mm VAS for pain rated the participant's
perception of pain intensity over the previous 7 days. The
CMS is an eighteen-item scale that diagnoses FM as per
the 1990 ACR criteria plus rates the amount of pain asso-
ciated with 4-kilograms of pressure applied to 18 tender
points commonly found in FM. The number of non-zero
scores out of 18 determined the total tender point count.
Tenderness and pain severity were measured by observ-
ing subject's reactions to 4-kg pressure on a 0-3 scale (0 =
no pain, 1 = some pain, 2 = verbal exclamation (e.g.
"ouch"), 3 = flinches/ moves away). Higher scores indicate
more pain, with a total possible range of 0 to 54. The PI
performed all tender point evaluations. Reliability for
scale items of the CMS as measured by Cronbach's alpha
was established to be 0.90 in this sample.
The Flannigan Quality of Life Scale (QOLS) is a16-item
Likert-type scale that assesses multiple areas of well-
being and life satisfaction [23]. Quality of life is measured
on a continuum where 1 = terrible and 7 = delighted. The
possible range of scores is from 16 to 112, with higher
scores indicating better well-being and quality of life. It
has been validated in an FM sample with an internal con-
sistency reliability alpha equaling 0.82 to 0.88 and test-
retest reliability of 0.84. Reliability for scale items of the
QOLS as measured by Cronbach's alpha was established
to be 0.92 in this sample.
The Jenkins Sleep Scale was used to assess sleep quality.
It is a 4-item scale divided over 5 equal time periods dur-
ing the preceding month that measures the quality of
sleep obtained [24].The scale has a possible range of
scores from 0 to 20, with higher scores indicating poorer
overall quality of sleep. The internal consistency coeffi-Ross et al. BMC Musculoskeletal Disorders 2010, 11:120
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cient for the scale was 0.79. Reliability for scale items of
the Jenkins Sleep Scale as measured by Cronbach's alpha
was established to be 0.80 in this sample.
Secondary measures
The  Demographic Data Form, an investigator-designed
questionnaire, was used to screen for inclusion/exclusion
criteria (past medical history, review of systems, current
medications) and to obtain demographic information
including age, gender, ethnicity/race; educational level;
marital and employment status; number of years with
FM; and body mass index (BMI). Body weight and height
were measured in kilograms and meters using a cali-
brated standing model scale (Detecto, Brooklyn, New
York). A standard formula of weight in kilograms divided
by height in meters squared was used to calculate BMI.
The Beck Depression Inventory-II-1973 Revision (BDI-
II-R) was used to screen for eligibility based on overall
depression severity and confirm the diagnosis of MDD.
The BDI-II-R is a 21-item scale that assesses intensity of
depression in clinical patients and in healthy controls and
has a reliability of 0.92 [25]. It has been widely used in
depression research and has been adapted for use in FM
by removing three items from the total score: fatigue,
sleep disturbance, and effort to get things done. These
symptoms correspond to FM symptomatology and there-
fore do not correlate well with MDD and overestimate the
level of depression. This adaptation, the BDI-A, has bet-
ter sensitivity (74% - 85%) and specificity (45% - 65%) in a
FM population than the original [26]. A score of 13 or
higher indicates a moderate level of depression, while
scores above 21 are fairly specific for MDD in FM
patients [26]. Reliability for scale items of the BDI-A was
determined to be a Cronbach's alpha of 0.87 in this
sample.
Statistical analyses
Data analyses were conducted using the Statistical Pack-
age for Social Sciences version 15.0 (SPSS, Chicago, Illi-
nois, USA). Significance levels were set at an alpha of ≤
0.05 and used a 2-tail distribution. Chi-square (χ2) tests
were used to determine if there were differences between
groups on nominal and ordinal level variables and also to
determine if diagnostic groups differed statistically on
prevalence of subtype-specific diagnostic criteria. To
measure the differences among diagnostic groups on
interval level variables, analysis of variance (ANOVA)
with Bonferroni post-hoc tests were conducted with an
adjusted alpha of 0.01 for multiple comparisons. To
assess the association between depression subtypes and
diagnostic criteria, multivariate analyses using logistic
r e g r e s s i o n  w i t h  o d d s  r a t i o s  w e r e  u s e d .  R e l a t i o n s h i p s
between each criterion and each MDD subtype (ADE vs.
MDE) were further examined using Spearman's Rho cor-
relation coefficients.
Results
Demographic characteristics
Convenience sampling identified 118 potential subjects
who were assessed for eligibility. Of those, 95% (n = 77/
118) met inclusion criteria, signed an informed consent
and completed Visit 1. One subject's data was later
excluded due to not meeting depression subtype group
inclusion criteria; thus the total sample consisted of 76
subjects. Ten subjects were unable to complete Visit 2;
therefore analyses for clinical characteristics were con-
ducted on the 66 subjects who completed all evaluations.
See Figure 1 for full recruitment and enrollment details.
All subjects (n= 63) were tested within an average of 17
(SD ± 20.43) days from the first assessment. Both pre-
menopausal and post-menopausal females were seen an
average of 14 days after their first assessment (Premeno-
pausal: SD ± 12.82; Postmenopausal: SD ± 14.53).
Subjects were on average 54 years old (± 12.7 yrs.) and
had experienced FM symptoms for an average of 18
years-Table 1. Nine of the total sample of 76 FM subjects
(11.8%) did not meet diagnostic criteria for MDD, 40
(52.6%) met criteria for ADE, and 27 (35.6%) for MDE.
The total sample reflected the expected predominance of
females (96%) versus males (4%) [27]. No significant dif-
ferences existed between groups on demographic vari-
ables except on gender (p = 0.01). Symptom duration
approached significance (p = 0.09) with the ADE sub-
group reporting FM symptoms an average of 6 years lon-
ger (20 years ± 15.1) than the MDE subgroup (14 years ±
8.8). The duration of symptoms in the non-MDD group,
(18 years ± 12.8), did not differ statistically from the ADE
group.
Clinical characteristics
As depicted in Table 2, groups differed on all clinical
characteristics except for number of tender points and
stiffness. All significant analyses of clinical features
remained significant at an adjusted Bonferroni alpha level
of 0.01 with the exceptions of physical impairment (p =
0.02) and pain severity as measured by the cumulative
myalgic score (p = 0.02). Pain as evidenced by the FIQ
VAS was highly significant (p < 0.001). Irrespective of
subtype, non-depressed subjects were generally less
symptomatic as measured by the total FIQ score (non-
MDD vs. ADE: p < 0.001; non-MDD vs. MDE: p < 0.001),
had a better quality of life (non-MDD vs. ADE: p < 0.001;
non-MDD vs. MDE: p < 0.001) and quality of sleep (non-
MDD vs. ADE: p = 0.007; non-MDD vs. MDE: p = 0.012)
compared to subjects with MDD.
Comparisons of the ADE subgroup versus the MDE
subgroup revealed depression severity was significantly
higher in the MDE group compared to the ADE group as
measured by the HamD-17 embedded in the SIGH-ADS
(p < 0.001). No significant differences in overall impact of
FM symptoms on daily life (p = 0.44), quality of life (p =Ross et al. BMC Musculoskeletal Disorders 2010, 11:120
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0.49), sleep quality (p = 1.0), pain severity (p = 0.2), or
tenderness (p = 1.0) existed between groups.
Subtype-specific criteria
As expected, the prevalence rates of the subtype-specific
diagnostic criteria for MDD with melancholic features as
per the DSM-IV-TR (Table 3) were found to be highest in
the MDE group and the criteria for MDD with atypical
features (Table 4) were highest in the ADE group.
Atypical Depressive Episode-specific criteria
While groups exhibited predominant symptom patterns
respective of their diagnostic classification (ADE vs.
MDE), some individual symptoms overlapped between
groups. In our sample, all subjects in the ADE group
reported mood reactivity, a mandatory criterion for ADE,
while 74.1% of the MDE and 44.4% of the non-MDD
groups also experienced this symptom. Over 67% of the
ADE group experienced weight gain or increased appe-
tite. Interestingly, 37% of the MDE group also reported
weight gain, while only 33% reported significant anorexia
or weight loss, which is the MDE-specific criterion. The
symptom of hypersomnia was highest in the ADE group
(35%) followed by the MDE group (18.5%). Over 71% of
the ADE group and 48.1% of the MDE group reported
interpersonal rejection sensitivity. Of interest, the major-
ity of the total sample reported leaden paralysis irrespec-
tive of diagnostic subgroup, with 100% of the ADE group,
96.3% of the MDE group and 44.4% of the non-MDD
group reporting this ADE-specific criterion. Groups dif-
fered significantly on chronicity of depression as mea-
sured by the number of episodes of depression [χ2 (2, n =
51) = 67.84, p = 0.007], with the ADE group having the
most episodes. Although groups did not differ on the
number of times suicide was attempted [χ2 (2, n = 61) =
4.16, p = 0.13], the highest prevalence of attempts were
made by the ADE group (38.1%; n = 8/21), followed by the
MDE group (15%; n = 3/20). None of the non-depressed
group had ever attempted suicide.
Melancholic Depressive Episode-specific criteria
The prevalence rate of anhedonia was 74% in the MDE
group while 12.5% of the ADE group also met this MDE-
specific criterion. Over 29% of the MDE group and 11.1%
of the ADE group reported lack of reactivity to usually
pleasurable stimuli. A distinct quality of depressed mood
was present in 100% of the MDE group; but 85% of the
ADE group also experienced this symptom. Depression
was regularly worse in the morning in 63% of the MDE
group and 32.5% of the ADE group. Early morning awak-
ening was highest in the MDE group (88.9%), but almost
half of the ADE group and over a third of the non-MDD
group also reported this symptom. Marked psychomotor
retardation or agitation was highest in the MDE group
(70.4%), yet 32.5% of the ADE group also endorsed it.
Excessive or inappropriate guilt was highest in the MDE
group (85.2%), compared to 40% in the ADE group.
Figure 1 Enrollment Flowchart
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mailed Invitation Letter                         (n = 1582) 
                                                                             
Letters returned undeliverable                (n = 100: 6.3%) 
Did not respond to invitation letter         (n = 1364: 86.2%) 
Responded to Invitation Letter                (n = 118: 7.5%) 
      
Excluded prior to orientation session      (n = 37: 31.4%)  
          Did not meet inclusion criteria      (n = 32: 86.5%) 
          Chose not to attend                        (n = 5: 13.5%)         
Enrollment 
(n = 77) 
FM no MDD (n = 9) 
Completed Visit 1 (n = 9) 
Did not complete (n = 0) 
FM/ADE (n = 40) 
Completed Visit 1 (n = 40) 
Did not complete (n = 0) 
FM/MDE (n = 27) 
Completed Visit 1 (n = 27) 
Did not complete (n = 0) 
                                                                  
Attended Orientation Sessions   (n = 81: 68.6%) 
     Assessed for Eligibility           (n = 81: 100%) 
     Ineligible                                (n = 4: 3.4%) 
     Enrolled in study                    (n = 77: 95.1%) 
FM no MDD (n= 9: 11.9%) 
Completed Visit 2 (n = 9)  
Did not complete (n = 0) 
FM/ADE (n = 40: 52.6%)  
Completed Visit 2 (n = 33) 
Did not complete (n = 7) 
Reasons did not complete: 
    Medical (n = 5)  
    Refused (n = 0) 
    Unable to schedule (n = 2) 
FM/MDE (n = 27: 35.5%) 
Completed Visit 2 (n = 24)    
Did not complete (n = 3) 
Reasons did not complete: 
    Medical (n = 1)  
    Refused (n = 1) 
    Unable to schedule (n = 1) 
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Table 1: Comparison of demographic data by diagnostic group: count (%), mean (±SD) and X2 values
DEMOGRAPHIC VARIABLES Total Sample No MDD ADE MDE BTW Group
(n = 76) 100% (n = 9) 11.8% (n = 40) 52.6% (n = 27) 35.6% P Values
Gender Female 73 (96.1%) 7 (77.8%) 39 (97%) 27 (100%) P = .01
Male 3 (3.9%) 2 (22.2%) 1 (2.5%) 0
Ethnicity Hispanic/Latino 5 (6.6%) 0 (0%) 3 (7.5%) 2 (7.4%) P = .81
Non-Hispanic/ Non-Latino 67 (88.2%) 8 (88.9%) 35 (87.5%) 24 (88.9%)
Not reported/Unknown 4 (5.3%) 1 (11.1%) 2 (5.0%) 1 (3.7%)
Race Asian 1 (1.3%) 01  ( 2 . 5 % ) 0P  =  . 1 6
Black/African American 2 (2.6%) 00 2  ( 7 . 4 % )
American Indian/ Alaskan 
Native
5 (6.6%) 2 (22.2%) 1 (2.5%) 2 (7.4%)
White 68 (89.5%) 7 (77.8%) 38 (95%) 23 (85.2%)
Educational Level Grade 10-12 6 (7.9%) 0 3 (7.5%) 3 (11.1%) P = .47
High School Diploma/GED 9 (11.8%) 0 6 (15%) 3 (11.1%)
Some college or trade 
school
33 (43.4%) 6 (66.7%) 14 (35%) 13 (48.2%)
College Degree or Higher 28 (36.8%) 3 (33.3%) 17 (44.5%) 8 (29.6%)
Marital Status Single/Separated 25 (32.9%) 0 12 (30%) 13 (48.1%) P = .14
Married/Living Together 47 (61.8%) 9 (100%) 26 (65%) 12 (44.5%)
Other 4 (5.3%) 0 2 (5%) 2 (7.4%)
Employment Status Full Time 16 (21.1%) 3 (33.3%) 8 (20%) 5 (18.5%) P = .70
Part Time 8 (10.5%) 0 4 (10%) 4 (14.8%)
Not employed out of home 52 (68.4%) 6 (66.7%) 28 (70%) 18 (66.7%)
Receiving disability No 53 (69.7%) 7 (77.8%) 27 (67.5%) 19 (70.4%) P = .83
Yes 23 (30.3%) 2 (22.2%) 13 (32.5%) 8 (29.6%)
Age in years 54.36 (12.67) 52.22 (11.16) 55.20 (12.95) 53.81 (13.05) P = .79
# of yrs with FM symptoms 18.05 (12.83) 20.11 (10.78) 20.36 (15.07) 14.11 (8.82) P = .09
# of years diagnosed with 
FM
7.72 (6.12) 10.22 (8.20) 7.40 (6.10) 7.35 (5.36) P = .43
BMI 30.55 (19.69) 29.51 (6.97) 32.05 (7.35) 29.08 (6.57) P = .28
Chi-square computed for nominal and ordinal data; ANOVA computed for interval data.Ross et al. BMC Musculoskeletal Disorders 2010, 11:120
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Odds ratios
The presence of the MDE-specific criteria of lack of reac-
tivity to usually pleasurable stimuli and distinct quality of
depressed mood predicted the diagnosis of MDE. Like-
wise, leaden paralysis and mood reactivity predicted the
diagnosis of ADE. However, while the associations of the
d i a g n o s t i c  s u b t y p e s  w i t h  t h e  a b o v e  f e a t u r e s  w e r e  v e ry
sensitive (the diagnosis of ADE was associated 100% of
the time with leaden paralysis) it was not very specific
(leaden paralysis was associated with the diagnosis of
MDE 47% of the time). As odds ratios cannot be com-
puted on items that perfectly predict each other, the
above four criteria were removed from further analyses.
All other odds ratios were positive, indicating subtype-
specific diagnostic criterion were highly associated with
their respective subtype. As seen in Table 3, the MDE
group was 20 times more likely to endorse anhedonia (p <
0.001); 3.5 times more likely to endorse depression being
worse in the mornings (p < 0.02); 10.8 times more likely
to endorse early morning awakening (p = 0.001); 4.9
times more likely to endorse psychomotor agitation or
retardation (p = 0.003); 6.2 times more likely to endorse
Table 2: Comparison of clinical characteristics for total sample and by diagnostic group: mean (± SD)
Clinical Characteristics No MDD ADE MDE P value  Between Group
Construct (Instrument) (n = 9) (n = 33) (n = 24) Significance
ABC
Pain-Presence 16.33 (2.50) 17.55 (1.00) 17.63 (.82) 0.60 NS
(Number of tender points)
Pain-Severity a-b*
(Cumulative Myalgic Score) 34.67 (11.70) 43.72 (8.29) 44.42 (8.65) 0.02 a-c*
Pain-Tenderness 4.11 (2.52) 6.58 (1.87) 7.54 (1.74) < 0.001 a-b*
(FIQ VAS) a-c*
Depression Severity 4.89 (3.72) 16.70 (5.78) 22.25 (3.93) < 0.001 a-b***
(HamD-17) a-c***
b-c***
Total FIQ Score  31.45 (18.57) 64.04 (17.72) 68.70 (10.75) < 0.001 a-b***
a-c***
Depression Severity  1.11 (1.67) 6.03 (5.51) 6.71 (2.49) < 0.001 a-b***
(FIQ VAS) a-c***
Stiffness 5.71 (4.27) 7.23 (2.28) 7.15 (2.58) 0.26 NS
(FIQ VAS)
Physical Impairment 2.98 (2.17) 4.89 (2.22) 5.32 (1.73) 0.02 a-b*
(FIQ) a-c*
Quality of life 95.56 (8.23) 69.58 (15.72) 63.83 (15.71) < 0.001 a-b***
(Flannigan) a-c***
Quality of sleep 0.006 a-b**
(Jenkins) 7.89 (7.52) 14.15 (4.78) 14.00 (4.78) a-c**
ANOVA computed for interval data. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.Ross et al. BMC Musculoskeletal Disorders 2010, 11:120
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Table 3: Prevalence rates of melancholic depressive episode-specific diagnostic criteria by diagnostic group
MDE CRITERIA No MDD ADE MDE χ2 ADE v. MDE (n = 67)
(A: n = 9) (B: n = 40) (C: n = 27) P value OR P Value
Anhedonia 0/9 5/39 7/27  TS < 0.001 20.0 < 0.001
(loss of pleasure in all, 0% 12.5% 74.1% a-b 0.57
or almost all activities) a-c < 0.001
b-c < 0.001
Lack of reactivity to 1/9 0/39 8/27 TS < 0.001 1.0
usually pleasurable stimuli 11.1% 0% 29.6% a-b 0.19 (Perfect Predictability)
a-c 0.40
b-c < 0.001
Distinct quality of 0/9 34/40 27/27 TS < 0.001 1.0
depressed mood 0% 85% 100 % a-b < 0.001 (Perfect Predictability)
a-c < 0.001
b-c 0.07
Depression regularly 1/9 13/41 17/27 TS < 0.007 3.5 0.02
worse in the morning 11.1% 32.5% 63% a-b 0.41
a-c 0.02
b-c 0.02
Early morning awakening 3/9 17/40 24/27 TS < 0.001 10.8 < 0.001
33.3% 42.5% 88.9% a-b 0.72
a-c 0.003
b-c < 0.001
Marked psychomotor 0/9 13/40 19/27 TS < 0.001 4.9 0.003
retardation or agitation 0% 32.5% 70.4% a-b 0.09
a-c < 0.001
b-c 0.003
Significant anorexia or 1/9 3/40 9/27 TS = 0.02 6.2 0.01
Weight loss 11.1% 7.5% 33.3% a-b 0.57
a-c 0.39
b-c 0.007
Excessive or 0/9 16/40 23/27 TS 0.001 8.6 < 0.001
inappropriate guilt 0% 40% 85.2% a-b 0.02
a-c < 0.001
b-c < 0.001
Abbreviations: TS, Total Sample; CI, Confidence Interval; OR, odds ratio. Italicized cells reflect highest prevalence rates among the 3 
diagnostic groups.Ross et al. BMC Musculoskeletal Disorders 2010, 11:120
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anorexia or weight loss, (p = 0.01); and 8.6 times more
likely to endorse excessive or inappropriate guilt (p =
0.001) than the ADE group. In contrast, Table 4 shows the
ADE group was more likely to endorse the ADE-specific
criteria of weight gain/ increased appetite (OR = 3.5, p =
0.02) and interpersonal rejection sensitivity (OR = 2.6, p
= 0.06) compared to the MDE group.
Correlations
The correlation matrix of the diagnosis of ADE versus
MDE with all five of the ADE-specific diagnostic features
and eight MDE-specific diagnostic features can be viewed
in an additional file (#2). In brief, there was a weak rela-
tionship between the diagnosis of ADE and significant
weight gain/ hyperphagia (r = 0.30, p = 0.013) and a mod-
erate relationship with mood reactivity (r = .42, p <
0.001). However, no significant associations existed
between the diagnosis of ADE and hypersomnia (r = .18,
p = 0.15), leaden paralysis (r = .15, p = 0.23) nor interper-
sonal rejection sensitivity (r = .23, p = 0.06).
For the MDE-diagnosed group, there was a strong rela-
tionship between the MDE-specific criteria anhedonia
(loss of pleasure in all, or almost all, activities) (r = 0.62, p
< 0.001), and moderate relationships with lack of reactiv-
ity to usually pleasurable stimuli (r = 0.45, p < 0.001),
Table 4: Prevalence rates of atypical depressive episode-specific diagnostic criteria by diagnostic group
ADE CRITERIA No MDD ADE MDE χ2 ADE v. MDE (n = 67)
(A: n = 9) (B: n = 40) (C: n = 27) P value OR P Value
Mood reactivity 4/9 40/40 20/27 TS < 0.001 1.0
44.4% 100% 74.1% a-b < 0.001 (Perfect Predictability)
a-c 0.13
b-c 0.001
Significant weight gain or 0/9 27/40 10/27 TS < 0.001 3.53 0.02
increased appetite 0% 67.5% 37% a-b < 0.001
a-c 0.04
b-c 0.02
Hypersomnia 0/9 14/40 5/27 TS  0.06 2.37 0.15
0% 35% 18.5% a-b 0.05
a-c 0.30
b-c 0.18
Leaden paralysis (i.e., heavy, 4/9 40/40 26/27 TS < 0.001 1.0
leaden feelings in arms or legs) 44.4% 100% 96.3% a-b < 0.001 (Perfect Predictability)
a-c 0.002
b-c 0.40
Long-standing pattern of 0/9 27/38 13/27 TS < 0.001 2.64 0.06
interpersonal rejection sensitivity 0% 71.1% 48.1% a-b < 0.001
a-c 0.01
b-c 0.07
Criteria not met for MDE during 9/9 40/40 0/27 TS < 0.001 0.007 0.007
the same episode 100% 100% 0% a-b 1.00
a-c < 0.001
b-c < 0.001
Abbreviations: TS, Total Sample; CI, Confidence Interval; OR, odds ratio. Italicized cells reflect highest prevalence rates among the 3 
diagnostic groups.Ross et al. BMC Musculoskeletal Disorders 2010, 11:120
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early morning awakening (r = 0.47, p < 0.001) and exces-
sive or inappropriate guilt (r = 0.45, p = < 0.001). Weak
relationships existed with marked psychomotor retarda-
tion or agitation (r = 0.37, p = 0.002), significant anorexia
or weight loss (r = 0.33, p = 0.006), depression worse in
the morning (r = 0.30, p = 0.013) and distinct quality of
depressed mood (r = 0.26, p = 0.035).
Discussion
The results reported herein provide evidence for the
occurrence of atypical and melancholic subtypes of
depression in FM subjects. Furthermore, these subjects
exhibited similar clinical features of ADE and MDE as has
been reported in other depressed non-FM populations
[13,28,29]. Interestingly, the ADE prevalence rate of
52.6% is approximately twice that of the 30% reported in
population studies of depressed people without FM. This
finding is consistent with ADE being more prevalent in
women and may be associated with the neuroendocrine
underpinnings of the preponderance of women versus
men (9:1) with FM [30]. The prevalence rate of MDE was
35.6%, which is more consistent with previous studies in
depressed non-FM populations which demonstrated a
prevalence of approximately 30% [31,32]. Demarcation of
MDD subtypes is a novel area of research in FM. Prior to
completing this pilot study, it was not known if subtype
prevalence in an FM sample would be consistent with the
prevalence of MDD subtypes previously identified in the
general population. We speculate the over-representation
of ADE is likely due to the above and ADE being more
prevalent in females in addition to the long-term effect of
chronic stress blunting HPA axis functions resulting in
lower cortisol levels. It is unclear as to why only one sub-
ject out of 77 was identified with the non-ADE/non-MDE
subtype. It is possible this finding was associated with self
selection bias, differences in symptom presentation of
MDD co-morbid with FM versus MDD alone, or the pos-
sibility the subject was transitioning from MDE to ADE.
A larger study is needed to better characterize depression
subtypes and their clinical features to determine if the
above finding is reproducible. Our team plans to investi-
gate this issue in future studies.
Clinical features of FM more severe in depressed groups
Our data substantiates previous reports that associate a
diagnosis of MDD in FM patients with more pain [33],
poorer sleep quality [34], poorer quality of life [35] and
greater functional impairment [36]. However, in the cur-
rent study, the specific subtype of MDD (ADE vs. MDE)
did not affect the intensity of the clinical characteristics
of FM with the exception of greater depression severity in
the MDE group.
Overlap of diagnostic criteria between subtypes
While conceptually, MDD subtype-specific criteria are
exclusive to their respective diagnostic subtype with no
overlap between subgroups, ours and other study data
[13,37] indicate diagnostic features that differentiate ADE
versus MDE do commonly overlap. Benazzi provides an
in-depth discussion of the concept of depressive subtype
symptom overlap in depressed non-FM populations and
presents the hypothesis of mood disorders representing a
continuum of overlapping disorders with common
underlying biological pathways versus being absolute cat-
egorical definitions [38]. Consistent with our findings,
Angst and colleagues [39] found in their 20 year prospec-
tive study that depressed non-FM subjects with pure mel-
ancholic and atypical depression exhibited many similar
characteristics, as evidenced by no significant differences
between groups on psychomotor retardation/agitation,
weight gain or feelings of excessive or inappropriate guilt.
In a large trial of 579 depressed non-FM patients (ADE, n
= 130; Non-ADE, n = 449) ADE symptoms were reported
in both groups, with the ADE group having the highest
prevalence of mood reactivity (100% vs. 77.7%), hyper-
somnia (36.2% vs. 16.8%), hyperphagia (53.1% vs. 21.8%),
leaden paralysis (60.8% vs. 28%), and interpersonal rejec-
tion sensitivity (75.4% vs. 40.9%) [13]. In line with Thase
and colleagues [40], we found that mood reactivity, a
mandatory criterion for ADE, was reported by the major-
ity of the MDE group and almost half of the non-MDD
group; which is also congruent with the observations of
Henkel and colleagues [41]. We cautiously speculate the
overlap in depressive subtype symptoms is likely due at
least in part to dysfunction of the HP A axis as well as
other neuroendocrine (e.g., serotonin and norepineph-
rine) and neuroimmune (e.g., pro-inflammatory cytokine
response) systems. Although Juruena and Cleare [42]
reviewed symptom overlap between ADE and other
MDD subtypes in populations similar to FM including
chronic fatigue syndrome, to our knowledge this study
was the first to evaluate ADE and MDE specific diagnos-
tic criterion in an FM population. Therefore, these find-
ings need to be replicated in a larger sample before any
conclusive assumption regarding the causes of the symp-
tom overlap can occur.
One final example of the non-specificity of diagnostic
criteria in our study was the finding that 100% of the ADE
group endorsed experiencing "leaden paralysis"; while
three-fourths of the MDE group also experienced this
symptom. As the reported prevalence of leaden paralysis
is significantly higher than reports from depressed non-
FM populations [37], we hypothesized there may be an
etiological link between leaden paralysis and the symp-
tom of stiffness, a common complaint of FM subjectsRoss et al. BMC Musculoskeletal Disorders 2010, 11:120
http://www.biomedcentral.com/1471-2474/11/120
Page 11 of 13
[43]. However we only found a week association between
these symptoms (r = 0.26, p = 0.03) indicating there may
be a mediating or moderating variable accounting for this
clinical observation.
Possible temporal association between length of time with 
FM and MDD subtypes
A non-significant (p = 0.09), yet potentially interesting
finding was a trend among MDD subtypes to differ in the
number of years that FM symptoms were present. Similar
to Wallace's findings [44], the ADE and non-MDD groups
had symptoms of FM for approximately six years longer
than the MDE group. It has been reported that non-FM
patients with ADE have a longer duration of symptoms
versus non-FM patients with MDE [39]. Gold and Chrou-
sos [15] have hypothesized that new onset FM is generally
associated with a hyperactive HPA axis characterized by
elevated levels of CRH and cortisol (a characteristic of
MDE), and that, over time, persistent stress results in
blunting of the HPA axis response (a characteristic of
ADE). Our data supports this notion, and we postulate
that this finding may explain disparities in previous
reports of HPA axis studies in FM [45-48], as both the
duration of FM symptoms and depression subtype might
be expected to influence HPA axis functioning.
Limitations
Certain groups were excluded to decrease risk to vulnera-
ble individuals (children, severely depressed people, peo-
ple with suicidal ideation) and to eliminate potential
confounding variables (persons with co-occurring rheu-
matic and pituitary disease, therapy with medications
known to alter HPA axis function), thus result may not
generalize to such individuals. Varying estrogen levels
across the menstrual cycle presents a potential confound-
ing variable in this study and necessitates more in-depth
measurement via standardized biochemical assays in
future studies. Furthermore, the sample was recruited
from patients seen at a tertiary care facility for FM con-
sultation and short-term management and an outpatient
mental health clinic specializing in mood disorders with
concurrent chronic pain, thus their symptoms may have
been more severe than patients managed in primary care
clinics. As the sample size was relatively small, these find-
ings need to be confirmed in a larger sample from a more
diverse population. The age of onset (before vs. after 20
years old), duration of symptoms (less than vs. greater
than 2 years) and chronicity of depression (number of
lifetime episodes) needs to be evaluated in future studies,
as these are proposed additions to the DSM-V diagnostic
criteria for depression with atypical features and may add
sensitivity and specificity to the diagnosis [49].
Future directions
There is much contemporary interest in trying to under-
stand psycho-neuro-endocrine dysfunction in relation to
the etiology of FM and chronic pain. Currently these
studies have yielded non-consistent and often contradic-
tory findings. We deduce that failure to distinguish
between depressive subgroups could have led to con-
founding results in studies that have measured HPA
activity, as the HPA axis in ADE is purported to be rela-
tively hypo-cortisolemic compared to the HPA axis in
MDE. For instance, recent research has reported that
interpersonal rejection sensitivity and the associated fear
of negative social evaluation is associated initially with a
hypercortisolemic response consistent with melancholic
depression and then later in life with hypocortisolemic
s t a t e s  s u c h  a s  a t y p i c a l  d e p r e s s i o n  [ 5 0 ] .  T h u s  b o t h  t h e
duration of a stressor and the nature of an associated
mood disorder are potentially important confounding
variables to consider in any HPA axis study in chronic
disease.
Conclusions
The results of this study confirm that depressed FM
patients commonly experience both atypical and melan-
cholic depressive features. In this study, atypical depres-
sion was 1.5 times more common than melancholic
depression. Furthermore, while the melancholic group
exhibit greater depression severity, those with atypical
depression appear to have fibromyalgia symptoms an
average of six years longer than those with melancholic
depression. The presence of depression subtypes in
depressed FM patients may have significant research and
clinical implications. In research, a failure to account for
depression subgroups may lead to regression towards the
means in some studies of HPA function. Classic research
provides evidence that the successful pharmacologic
treatment of ADE differs from the treatment for MDE
[51,52] and is proposed to be due to differing biological
dysfunction of the HPA axis, locus ceruleus-noradrener-
gic system and the physiological stress systems. Thus,
depression subtypes need to be addressed in future stud-
ies and clinical practice to eliminate the possibility of
making erroneous conclusions from the data.
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